drugset / Trial / NCT01264094

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

NCT01264094

Phase 4 Terminated 200 enrolled Bukwang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period.

Timeline

Start
2009-11
Primary completion
2014-11
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 30 mg